RCT: Lactoferrin Versus Placebo in ICU Patients

• Sponsor: Mansoura University Hospital (Other)
• Overall Status: Not yet recruiting
• CT.gov ID: NCT05936528
• Collaborator: (none)
• Enrollment: 650
• Location: 1
• Arms: 2
• Anticipated Duration (Months): 6.9
• Patients Per Site Per Month: 93.8

Study Details

Study Description

Brief Summary

Introduction:

Lactoferrin has several uses due to its effects. It has anti-inflammatory, antioxidant, immunomodulatory, antibacterial, antifungal, and antiviral effects. Its safety is proven by food and drug administration.

Aims:

The objective is to study the effect of lactoferrin on improving clinical outcomes in ICU patients when compared to placebo, and also to evaluate its safety.

Patients and populations:

A sample of 650 patients (325 patients in both groups A, and B) who will be admitted to ICU departments in Mansoura university hospital will be used to represent the population in ICU.

Methods:

A sample of 650 participants was randomized 1:1 into two groups (group A (325 patients), and group B (325 patients)).

This study is a double-blind, randomized controlled clinical trial. Randomization was performed by independent clinical pharmacists working in hospital ICU departments.

Condition or Disease	Intervention/Treatment	Phase
Critical Illness	Drug: Lactoferrin	Phase 4

Detailed Description

1. Introduction

1.1. Lactoferrin molecule

Lactoferrin (LF) is iron linking milk protein, as its name suggests (lacto refer to milk protein, and ferrin means iron. LF helps to modulate iron levels in the body [1-3]. LF is a part of the milk whey protein. The colostrum (the first milk produced in mothers after delivery) has seven times more LF than mature milk [4].

LF is found in the body everywhere needing immunity against microbes. it is found in many organs like kidneys, lungs, gallbladder, pancreas, intestine, liver, prostate, and also in the body fluids like saliva, tears, sperm, cerebrospinal fluid, urine, bronchial secretions, vaginal discharge, synovial fluid, umbilical cord blood, blood plasma, and the immune cells [1,2,4].

LF has many beneficial effects in the body. It has antioxidant, immunomodulatory, anti-inflammatory, antimicrobial, and antiviral effect [5,6] as shown in figure 1 [7].

Figure 1: different effects of lactoferrin [7]

1.2. Lactoferrin as antioxidant molecule

The body is affected by several factors such as pathogens, environmental pollutants, and toxins. This leads to the development and accumulation of reactive oxygen species (ROS) in the body which is known as oxidative stress. ROS can cause many diseases like cancer; so, antioxidant effect produced by several molecule as LF can stop the harm induced by ROS [8,9]. The target is to maintain the balance between antioxidant molecule and ROS. LF is a type of antioxidant molecules which enhance the activity of endogenous antioxidant pathways [10].

LF act as a neuroprotective agent in Parkinson's disease and Alzheimer's disease [11-13]. It also protects against osteoporosis by inhibition of osteoblast activity and its antioxidant effect [14,15].

LF improve glucose metabolism in patients with type 2 diabetes mellitus via enhancement of the insulin-mediating response [16-19] and prevent obesity due to imbalance in body fat metabolism [17,20]. It also reduces blood pressure in hypertension [21].

1.3. Lactoferrin as antipathogenic and immunomodulating molecule

LF has antibacterial activity against Gram-positive and Gram-negative bacteria, as it kills pathogens, prevents the biofilm formation by Staphylococcus aureus or Pseudomonas aeruginosa [22,23]. LF also prevent viral, bacterial, fungal and protozoal gastrointestinal tract infections [22,24]. LF enhance the treatment of Helicobacter pylori gastric infection [25]. LF also protect against endotoxemia, bacteremia, sepsis and necrotic enteritis after partial bowel resection [26] and in neonates [27-29].

LF act as antibacterial agent by killing the bacterial cells, modulation of the immune system. In addition, LF binds to iron lead to its absence in media causing inhibition of bacterial growth, which protects the body from infection [30].

LF possess an antiviral activity and enhances the effect of antiviral drugs [31].

LF act as antiviral agent by blocking the pathogen's surface receptors and prevent it from binding to the target cell, for example, binding to angiotensin converting enzyme II receptors which used by severe acute respiratory syndrome- coronavirus 2 (SARS-CoV-2) to pass cell membrane and thus inhibit virus entry into the cell [32-34].

LF also has antifungal effect against dermatophytes and enhance the effect of antifungal drugs [35,36]. In addition, LF has an antiparasitic effect in treatment of toxoplasmosis and malaria [37].

It also has an immunomodulating effect, stimulating the body to synthesize cytokines and chemokines as well as accelerating the maturation of the immune system cells [3,38,39].

1.4. Lactoferrin as anti-inflammatory molecule

LF possess also anti-inflammatory activity in non-infectious disorders such as allergies, arthritis, cancer [40] and inflammatory colitis [41,42]. LF has anti-inflammatory effect by inhibition of ROS to prevent lipid peroxidation by chelating iron. LF also enhance the production of anti-inflammatory cytokines (IL-10), and suppressing the production of pro-inflammatory cytokines (IL-6, IL-8, IL-1b, and tumor necrosis factor (TNF-α)). In addition, LF enter into mast cells and interact with the inflammatory proteases (chymase, cathepsin G, and tryptase) [43].

Lactoferrin mainly inhibit the production of ROS and further lipid peroxidation by chelating iron which is essential for their production so inhibiting the inflammatory pathway [44].

1.5. Lactoferrin for anemia of inflammation

LF treats inflammatory disorders by increasing ferroprotein production, and by decreasing IL-6 level to redistribute endogenous iron between blood and tissue. So, LF is used as therapy for anemia caused by inflammation [45-47].

1.6. Safety of lactoferrin use

LF is safe for use. Its safety is proved by the Food and Drug Administration [48]. However, bovine LF, as an ingredient in cow's milk, may cause an hypersensitivity, So, lactoferrin use has a risk of allergic reaction, and contraindicated in case of hypersensitivity to cow's milk proteins, and in lactose intolerance [49,50]. Other side effects of LF are mild include: stomach pain, vomiting, and constipation [51].

1. Aim of the study

The objective is to study the effect of lactoferrin on improving clinical outcomes in ICU patients when compared to placebo, and also to evaluate its safety.

1. Methods

3.1. Study design

The research will be a double-blind, randomized controlled clinical trial to evaluate the efficacy and safety of a drug. Randomization will be 1:1 and achieved by independent clinical pharmacists who are working in ICU departments of the hospital. Both patients and investigators will be blinded for identification of treatment, and placebo groups. Allocation of patients into their groups will be made after checking for meeting inclusion and not meeting exclusion criteria within 24 hours of the admission to ICU. All patients will receive the standard of care at admission.

3.2. Patients and populations

A sample of 650 patients (325 patients in both groups A, and B) who will be admitted to ICU departments in Mansoura university hospital will be used to represent the population in ICU.

3.3. Intervention

Doses of LF from 100 to 4500 mg daily for its indications are safe without significant toxicities [52]. Patients will be randomized (1:1) into two groups (group A, and group B). A dose of 200 mg orally twice daily (400 mg per day), shows improvements in platelet count, lymphocyte count, and serum hemoglobin level [53].

So, this dose will be chosen in this study. One group will receive a two sachet of 100 mg lactoferrin enterally (either orally or by Ryle tube) every 12 hours (400 mg daily) for 28 days plus the standard of care. another group will receive the standard of care only.

3.4 Statistical analysis and sample size

Statistical analysis:

Intention-to-treat (ITT) strategy will be used in this study. Categorical variables will be presented as proportion and percent. Continuous variables will be presented as mean (standard deviation) if normally distributed or as a median (IQR) or (25th-75th percentile) for non-normally distributed data Mann-Whitney test or t-test will be used to compare baseline characteristics and outcomes between the two groups. In comparison between the two groups, Mann-Whitney test will be used to compare proportions for non-parametric data (nominal or categorical), and to compare medians for non- normally distributed continuous parametric data. While t-test will be used only to compare means in case normally distributed continuous parametric. So, distributions of continuous data will be tested in order to know the correct test to be used in comparison of parametric data between the two groups.

Investigators will report the 95% confidence interval and the P-value for our statistical tests with level of statistical significance will be p-value < 0.05.

Regression analysis will be performed, if there is a statistically significant differences between the baseline characteristics including age, gender, No. of comorbidities (DM, hypertension (HTN), ischemic heart disease (IHD), atrial fibrillation (AF), COPD) in order to exclude the effect of these confounding variables on the study outcomes Investigators will compare the 28-day all-cause mortality rate, incidence of hypersensitivity reactions, and need for invasive mechanical ventilation (IMV) using the Mann-Whitney test. while t-test will be used to compare the day of death, duration of need for oxygen therapy and IMV, and duration of ICU stay, and all parameter measured in the study if they will be normally distributed, but if they will be non-normally distributed, Mann-Whitney test will be used instead.

. Statistical analysis will be achieved with SPSS software, version 26.

Sample size:

The power of trial will depend on the primary outcome (28-day mortality). The proportion of ICU Population to all hospital population is about 25% A total sample sizes of 634 patients would achieve at least 80 % (0.8) power to detect a risk difference of 0.2 (20%) in the 28-day all-cause mortality (primary outcome) between alternative hypothesis and the null hypothesis (proportions of two groups are 0.5) with a significance level (α) of 0.05 and 95% confidence level proportion in Clincalc.com calculator [55]. To compensate for the estimated loss-to-follow-up and increase the study power more than 80%, Investigators will increase the sample size in both groups to be 650 patients (317 in each study group).

The mortality data was estimated from the average mortality in August, September, and October 2023 at the Mansoura University Hospital ICU departments among all hospitalized patients. Mortality rate is found to be about 720 cases in these 3 months (240 cases / month) in ICU patients receiving the standard of care. The online system has been used to obtain mortality rate in these three months. The hypothesis is that LF will decrease mortality by 20% so mortality rate will be decreased from 240 to 192 per month.

1. Data Quality and Safety

Investigators will collect the data from hospital system directly into an excel sheet, Patient confidentiality will be kept before, during and after the study. Patients who will be discharged before 28 days of hospital stay, will be communicated at day 28 in order to know mortality at day 28.

1. Publishing the study results and funding

Due to size limitations in publishing the research as one paper in a journal. Investigators aim to divide this research into three papers and publish these papers in peer-review journals (3 stage publications).

Funding there is no funding source for this study

Conflict of interest The investigators declare no relevant conflict of interest

1. Ethical Considerations

Ethical approval will be taken from the Institutional Review Board (IRB), faculty of medicine, Mansoura university, Research Ethics Committees in faculty of medicine and pharmacy, Tanta university. Benefits of the intervention to the patients outweigh expected risks. Informed consents will be obtained from all participants in this research. Privacy of participants and confidentially of data will be maintained. Any unexpected risk appeared during the research will be cleared to participants, the IRB, and ethical committees on time. All study procedures will obey the standard of the Declaration of Helsinki (1964) principles

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 650 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Triple (Participant, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Clinical Research to Study the Effect of Lactoferrin Versus Placebo in Improving Clinical Outcomes in ICU Patients, a Double-blinded RCT
• Anticipated Study Start Date: Nov 1, 2023
• Anticipated Primary Completion Date: Apr 30, 2024
• Anticipated Study Completion Date: May 30, 2024

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Lactoferrin Lactoferrin 100 mg sachets with a dose of 200 mg (2 sachets) orally twice daily (400 mg per day) In addition to standard of care	Drug: Lactoferrin; antioxidant, immunomodulatory, anti-inflammatory, antimicrobial, and antiviral effect
No Intervention: Placebo Standard of care only no intervention by lactoferrin

Outcome Measures

Primary Outcome Measures

1. 28-days mortality rate [28 days]

   Dead or alive

2. Number of Participants With any allergic or hypersensitivity reactions [up to 60 days]

   incidence of any allergic or hypersensitivity reactions

Secondary Outcome Measures

1. Day of death [up to 60 days]

   Death day

2. Incidence of need for Invasive Mechanical Ventilation [up to 60 days]

   yes or no

3. Oxygen Support Duration [up to 60 days]

   Duration of need for Oxygen Support

4. Duration of ICU stay [up to 60 days]

   ICU stay duration

5. White blood cells (WBCs) counts on day 3 [day 3]

   Leukocytes count on day 3

6. White blood cells (WBCs) counts on day 7 [day 7]

   Leukocytes count on day 7

7. White blood cells (WBCs) counts on day 14 [day 14]

   Leukocytes count on day 14

8. White blood cells (WBCs) counts on day 28 [day 28]

   Leukocytes count on day 28

9. Neutrophils counts on day 3 [day 3]

   Neutrophils counts on day 3

10. Neutrophils counts on day 7 [day 7]

    Neutrophils counts on day 7

11. Neutrophils counts on day 14 [day 14]

    Neutrophils counts on day 14

12. Neutrophils counts on day 28 [day 28]

    Neutrophils counts on day 28

13. Lymphocytes counts on day 3 [day 3]

    Lymphocytes counts on day 3

14. Lymphocytes counts on day 7 [day 7]

    Lymphocytes counts on day 7

15. Lymphocytes counts on day 14 [day 14]

    Lymphocytes counts on day 14

16. Lymphocytes counts on day 28 [day 28]

    Lymphocytes counts on day 28

17. Hemoglobin concentration on day 3 [day 3]

    Hemoglobin concentration on day 3

18. Hemoglobin concentration on day 7 [day 7]

    Hemoglobin concentration on day 7

19. Hemoglobin concentration on day 14 [day 14]

    Hemoglobin concentration on day 14

20. Hemoglobin concentration on day 28 [day 28]

    Hemoglobin concentration on day 28

21. Hematocrit concentration on day 3 [day 3]

    Hematocrit concentration on day 3

22. Hematocrit concentration on day 7 [day 7]

    Hematocrit concentration on day 7

23. Hematocrit concentration on day 14 [day 14]

    Hematocrit concentration on day 14

24. Hematocrit concentration on day 28 [day 28]

    Hematocrit concentration on day 28

25. Platelets counts on day 3 [day 3]

    Platelets counts on day 3

26. Platelets counts on day 7 [day 7]

    Platelets counts on day 7

27. Platelets counts on day 14 [day 14]

    Platelets counts on day 14

28. Platelets counts on day 28 [day 28]

    Platelets counts on day 28

29. C-reactive Protein (CRP) concentration on day 3 [day 3]

    C-reactive Protein (CRP) concentration on day 3

30. C-reactive Protein (CRP) concentration on day 7 [day 7]

    C-reactive Protein (CRP) concentration on day 7

31. C-reactive Protein (CRP) concentration on day 14 [day 14]

    C-reactive Protein (CRP) concentration on day 14

32. C-reactive Protein (CRP) concentration on day 28 [day 28]

    C-reactive Protein (CRP) concentration on day 28

33. lactate dehydrogenase (LDH) concentration on day 3 [day 3]

    lactate dehydrogenase (LDH) concentration on day 3

34. lactate dehydrogenase (LDH) concentration on day 7 [day 7]

    lactate dehydrogenase (LDH) concentration on day 7

35. lactate dehydrogenase (LDH) concentration on day 14 [day 14]

    lactate dehydrogenase (LDH) concentration on day 14

36. lactate dehydrogenase (LDH) concentration on day 28 [day 28]

    lactate dehydrogenase (LDH) concentration on day 28

37. Ferritin concentration on day 3 [day 3]

    Ferritin concentration on day 3

38. Ferritin concentration on day 7 [day 7]

    Ferritin concentration on day 7

39. Ferritin concentration on day 14 [day 14]

    Ferritin concentration on day 14

40. Ferritin concentration on day 28 [day 28]

    Ferritin concentration on day 28

41. D-dimer concentration on day 3 [day 3]

    D-dimer concentration on day 3

42. D-dimer concentration on day 7 [day 7]

    D-dimer concentration on day 7

43. D-dimer concentration on day 14 [day 14]

    D-dimer concentration on day 14

44. D-dimer concentration on day 28 [day 28]

    D-dimer concentration on day 28

45. Sequential Organ Function Assessment (SOFA) Score on day 3 [day 3]

    minimum 0 to maximum 24, higher scores mean worse outcomes

46. Sequential Organ Function Assessment (SOFA) Score on day 7 [day 7]

    minimum 0 to maximum 24, higher scores mean worse outcomes

47. Sequential Organ Function Assessment (SOFA) Score on day 14 [day 14]

    minimum 0 to maximum 24, higher scores mean worse outcomes

48. Sequential Organ Function Assessment (SOFA) Score on day 28 [day 28]

    minimum 0 to maximum 24, higher scores mean worse outcomes

49. Aspartate Aminotransferase (AST) concentration on day 3 [day 3]

    Aspartate Aminotransferase (AST) concentration on day 3

50. Aspartate Aminotransferase (AST) concentration on day 7 [day 7]

    Aspartate Aminotransferase (AST) concentration on day 7

51. Aspartate Aminotransferase (AST) concentration on day 14 [day 14]

    Aspartate Aminotransferase (AST) concentration on day 14

52. Aspartate Aminotransferase (AST) concentration on day 28 [day 28]

    Aspartate Aminotransferase (AST) concentration on day 28

53. Alanine Aminotransferase (ALT) concentration on day 3 [day 3]

    Alanine Aminotransferase (ALT) concentration on day 3

54. Alanine Aminotransferase (ALT) concentration on day 7 [day 7]

    Alanine Aminotransferase (ALT) concentration on day 7

55. Alanine Aminotransferase (ALT) concentration on day 14 [day 14]

    Alanine Aminotransferase (ALT) concentration on day 14

56. Alanine Aminotransferase (ALT) concentration on day 28 [day 28]

    Alanine Aminotransferase (ALT) concentration on day 28

57. Albumin concentration on day 3 [day 3]

    Albumin concentration on day 3

58. Albumin concentration on day 7 [day 7]

    Albumin concentration on day 7

59. Albumin concentration on day 14 [day 14]

    Albumin concentration on day 14

60. Albumin concentration on day 28 [day 28]

    Albumin concentration on day 28

61. Bilirubin concentration on day 3 [day 3]

    Bilirubin concentration on day 3

62. Bilirubin concentration on day 7 [day 7]

    Bilirubin concentration on day 7

63. Bilirubin concentration on day 14 [day 14]

    Bilirubin concentration on day 14

64. Bilirubin concentration on day 28 [day 28]

    Bilirubin concentration on day 28

65. Serum Creatinine (S.Cr) concentration on day 3 [day 3]

    Serum Creatinine (S.Cr) concentration on day 3

66. Serum Creatinine (S.Cr) concentration on day 7 [day 7]

    Serum Creatinine (S.Cr) concentration on day 7

67. Serum Creatinine (S.Cr) concentration on day 14 [day 14]

    Serum Creatinine (S.Cr) concentration on day 14

68. Serum Creatinine (S.Cr) concentration on day 28 [day 28]

    Serum Creatinine (S.Cr) concentration on day 28

69. Creatinine clearance (Cr.Cl) rate on day 3 [day 3]

    Creatinine clearance (Cr.Cl) rate on day 3

70. Creatinine clearance (Cr.Cl) rate on day 7 [day 7]

    Creatinine clearance (Cr.Cl) rate on day 7

71. Creatinine clearance (Cr.Cl) rate on day 14 [day 3]

    Creatinine clearance (Cr.Cl) rate on day 14

72. Creatinine clearance (Cr.Cl) rate on day 28 [day 28]

    Creatinine clearance (Cr.Cl) rate on day 28

73. Duration of hospitalization [up to 60 days]

    Duration of hospitalization

Other Outcome Measures

1. Glasgow Coma Score (GCS) on day 3 [day 3]

   minimum 0 to maximum 15, higher scores mean better outcomes

2. Glasgow Coma Score (GCS) on day 7 [day 7]

   minimum 0 to maximum 15, higher scores mean better outcomes

3. Glasgow Coma Score (GCS) on day 14 [day 14]

   minimum 0 to maximum 15, higher scores mean better outcomes

4. Glasgow Coma Score (GCS) on day 28 [day 28]

   minimum 0 to maximum 15, higher scores mean better outcomes

5. Arterial Oxygen Pressure / Fraction Inspired of Oxygen (PaO2/FiO2) on day 3 [day 3]

   Arterial Oxygen Pressure / Fraction Inspired of Oxygen (PaO2/FiO2) on day 3

6. Arterial Oxygen Pressure / Fraction Inspired of Oxygen (PaO2/FiO2) on day 7 [day 7]

   Arterial Oxygen Pressure / Fraction Inspired of Oxygen (PaO2/FiO2) on day 7

7. Arterial Oxygen Pressure / Fraction Inspired of Oxygen (PaO2/FiO2) on day 14 [day 14]

   Arterial Oxygen Pressure / Fraction Inspired of Oxygen (PaO2/FiO2) on day 14

8. Arterial Oxygen Pressure / Fraction Inspired of Oxygen (PaO2/FiO2) on day 28 [day 28]

   Arterial Oxygen Pressure / Fraction Inspired of Oxygen (PaO2/FiO2) on day 28

9. Oxygen saturation on day 3 [day 3]

   Oxygen saturation at day 3

10. Oxygen saturation on day 7 [day 7]

    Oxygen saturation at day 7

11. Oxygen saturation on day 14 [day 14]

    Oxygen saturation at day 14

12. Oxygen saturation on day 28 [day 28]

    Oxygen saturation at day 28

Eligibility Criteria

Criteria

• Ages Eligible for Study: N/A and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• patients admitted to ICU, of any age and gender.

Exclusion Criteria:

• inability to give informed consent by patients or their relative,

• history of hypersensitivity to milk products,

• history of lactoferrin use in the past 6 months,

• patients with lactose intolerance,

• patients with no enteral access to administer LF either orally or by Ryle tube,

• patients who are expected to die within 48 hours, and

• patients with poor oral absorption as in case of shock and resected bowel.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Mansoura University hospital	Mansoura	El-dakhlia	Egypt

Sponsors and Collaborators

• Mansoura University Hospital

Investigators

• Principal Investigator: Ahmed H Hassan, Pharmacist, Mansoura University Hospital

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

• Study data

Publications

• Abdelhamid M, Jung CG, Zhou C, Abdullah M, Nakano M, Wakabayashi H, Abe F, Michikawa M. Dietary Lactoferrin Supplementation Prevents Memory Impairment and Reduces Amyloid-beta Generation in J20 Mice. J Alzheimers Dis. 2020;74(1):245-259. doi: 10.3233/JAD-191181.
• Actor JK, Hwang SA, Kruzel ML. Lactoferrin as a natural immune modulator. Curr Pharm Des. 2009;15(17):1956-73. doi: 10.2174/138161209788453202.
• Alexander DB, Iigo M, Abdelgied M, Ozeki K, Tanida S, Joh T, Takahashi S, Tsuda H. Bovine lactoferrin and Crohn's disease: a case study. Biochem Cell Biol. 2017 Feb;95(1):133-141. doi: 10.1139/bcb-2016-0107. Epub 2016 Nov 30.
• Algahtani FD, Elabbasy MT, Samak MA, Adeboye AA, Yusuf RA, Ghoniem ME. The Prospect of Lactoferrin Use as Adjunctive Agent in Management of SARS-CoV-2 Patients: A Randomized Pilot Study. Medicina (Kaunas). 2021 Aug 19;57(8):842. doi: 10.3390/medicina57080842.
• Arnold RR, Brewer M, Gauthier JJ. Bactericidal activity of human lactoferrin: sensitivity of a variety of microorganisms. Infect Immun. 1980 Jun;28(3):893-8. doi: 10.1128/iai.28.3.893-898.1980.
• Artym J, Zimecki M. Antimicrobial and Prebiotic Activity of Lactoferrin in the Female Reproductive Tract: A Comprehensive Review. Biomedicines. 2021 Dec 17;9(12):1940. doi: 10.3390/biomedicines9121940.
• Artym J, Zimecki M. Milk-derived proteins and peptides in clinical trials. Postepy Hig Med Dosw (Online). 2013 Aug 6;67:800-16. doi: 10.5604/17322693.1061635.
• Baker HM, Baker EN. A structural perspective on lactoferrin function. Biochem Cell Biol. 2012 Jun;90(3):320-8. doi: 10.1139/o11-071. Epub 2012 Jan 31.
• Berlutti F, Pantanella F, Natalizi T, Frioni A, Paesano R, Polimeni A, Valenti P. Antiviral properties of lactoferrin--a natural immunity molecule. Molecules. 2011 Aug 16;16(8):6992-7018. doi: 10.3390/molecules16086992.
• Bielecka M., Cichosz G., Czeczot H. Antioxidant, antimicrobial and anticarcinogenic activities of bovine milk proteins and their hydrolysates-A review. Int. Dairy J. 2021; 127:105208. doi: 10.1016/j.idairyj.2021.105208.
• Bukowska-Osko I, Popiel M, Kowalczyk P. The Immunological Role of the Placenta in SARS-CoV-2 Infection-Viral Transmission, Immune Regulation, and Lactoferrin Activity. Int J Mol Sci. 2021 May 28;22(11):5799. doi: 10.3390/ijms22115799.
• Carro E, Bartolome F, Bermejo-Pareja F, Villarejo-Galende A, Molina JA, Ortiz P, Calero M, Rabano A, Cantero JL, Orive G. Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin. Alzheimers Dement (Amst). 2017 May 26;8:131-138. doi: 10.1016/j.dadm.2017.04.002. eCollection 2017.
• Chang R, Ng TB, Sun WZ. Lactoferrin as potential preventative and adjunct treatment for COVID-19. Int J Antimicrob Agents. 2020 Sep;56(3):106118. doi: 10.1016/j.ijantimicag.2020.106118. Epub 2020 Jul 30.
• Chen XW, Li YH, Zhang MJ, Chen Z, Ke DS, Xue Y, Hou JM. Lactoferrin ameliorates aging-suppressed osteogenesis via IGF1 signaling. J Mol Endocrinol. 2019 Jul;63(1):63-75. doi: 10.1530/JME-19-0003.
• Cutone A, Frioni A, Berlutti F, Valenti P, Musci G, Bonaccorsi di Patti MC. Lactoferrin prevents LPS-induced decrease of the iron exporter ferroportin in human monocytes/macrophages. Biometals. 2014 Oct;27(5):807-13. doi: 10.1007/s10534-014-9742-7. Epub 2014 May 3.
• Cutone A, Rosa L, Lepanto MS, Scotti MJ, Berlutti F, Bonaccorsi di Patti MC, Musci G, Valenti P. Lactoferrin Efficiently Counteracts the Inflammation-Induced Changes of the Iron Homeostasis System in Macrophages. Front Immunol. 2017 Jun 15;8:705. doi: 10.3389/fimmu.2017.00705. eCollection 2017.
• Food and drug administration. GRAS Notice (GRN), No. 669, Cow's Milk-Derived Lactoferrin. [(accessed on 12 September 2021)]; Available online: https://www.fda.gov
• Gonzalez-Sanchez M, Bartolome F, Antequera D, Puertas-Martin V, Gonzalez P, Gomez-Grande A, Llamas-Velasco S, Herrero-San Martin A, Perez-Martinez D, Villarejo-Galende A, Atienza M, Palomar-Bonet M, Cantero JL, Perry G, Orive G, Ibanez B, Bueno H, Fuster V, Carro E. Decreased salivary lactoferrin levels are specific to Alzheimer's disease. EBioMedicine. 2020 Jul;57:102834. doi: 10.1016/j.ebiom.2020.102834. Epub 2020 Jun 22.
• Goodman RE, Taylor SL, Yamamura J, Kobayashi T, Kawakami H, Kruger CL, Thompson GP. Assessment of the potential allergenicity of a Milk Basic Protein fraction. Food Chem Toxicol. 2007 Oct;45(10):1787-94. doi: 10.1016/j.fct.2007.03.014. Epub 2007 Mar 28.
• He S, McEuen AR, Blewett SA, Li P, Buckley MG, Leufkens P, Walls AF. The inhibition of mast cell activation by neutrophil lactoferrin: uptake by mast cells and interaction with tryptase, chymase and cathepsin G. Biochem Pharmacol. 2003 Mar 15;65(6):1007-15. doi: 10.1016/s0006-2952(02)01651-9.
• Ikeda Y, Tajima S, Izawa-Ishizawa Y, Kihira Y, Ishizawa K, Yoshida S, Aihara K, Tsuchiya K, Tamaki T. Bovine milk-derived lactoferrin exerts proangiogenic effects in an Src-Akt-eNOS-dependent manner in response to ischemia. J Cardiovasc Pharmacol. 2013 May;61(5):423-9. doi: 10.1097/FJC.0b013e318287d526.
• Jenssen H, Hancock RE. Antimicrobial properties of lactoferrin. Biochimie. 2009 Jan;91(1):19-29. doi: 10.1016/j.biochi.2008.05.015. Epub 2008 Jun 5.
• Kaczmarek N, Jamka M, Walkowiak J. [An association of selected polymorphisms of the lactoferrin gene and genes for lactoferrin receptors in the prevalence of metabolic disorders in obese subjects]. Pol Merkur Lekarski. 2020 Apr 22;48(284):120-123. Polish.
• Kane SP. Sample Size Calculator, ClinCalc: https://clincalc.com/stats/samplesize.aspx. Updated July 24, 2019. Accessed May 25, 2023.
• Konishi M, Iwasa M, Yamauchi K, Sugimoto R, Fujita N, Kobayashi Y, Watanabe S, Teraguchi S, Adachi Y, Kaito M. Lactoferrin inhibits lipid peroxidation in patients with chronic hepatitis C. Hepatol Res. 2006 Sep;36(1):27-32. doi: 10.1016/j.hepres.2006.06.005. Epub 2006 Jul 20.
• Kowalczyk P, Kaczynska K, Kleczkowska P, Bukowska-Osko I, Kramkowski K, Sulejczak D. The Lactoferrin Phenomenon-A Miracle Molecule. Molecules. 2022 May 4;27(9):2941. doi: 10.3390/molecules27092941.
• Kowalczyk P, Sulejczak D, Kleczkowska P, Bukowska-Osko I, Kucia M, Popiel M, Wietrak E, Kramkowski K, Wrzosek K, Kaczynska K. Mitochondrial Oxidative Stress-A Causative Factor and Therapeutic Target in Many Diseases. Int J Mol Sci. 2021 Dec 13;22(24):13384. doi: 10.3390/ijms222413384.
• Legrand D, Pierce A, Elass E, Carpentier M, Mariller C, Mazurier J. Lactoferrin structure and functions. Adv Exp Med Biol. 2008;606:163-94. doi: 10.1007/978-0-387-74087-4_6.
• León-Sicairos N., Ordaz-Pichardo C., Carrero J.C., de la Garza M. Natural Remedies in the Fight Against Parasites. Intechopen; London, UK: 2017. Lactoferrin in the Battle against Intestinal Parasites: A Review.
• Lepanto MS, Rosa L, Cutone A, Conte MP, Paesano R, Valenti P. Efficacy of Lactoferrin Oral Administration in the Treatment of Anemia and Anemia of Inflammation in Pregnant and Non-pregnant Women: An Interventional Study. Front Immunol. 2018 Sep 21;9:2123. doi: 10.3389/fimmu.2018.02123. eCollection 2018.
• Li L, Ren F, Yun Z, An Y, Wang C, Yan X. Determination of the effects of lactoferrin in a preclinical mouse model of experimental colitis. Mol Med Rep. 2013 Oct;8(4):1125-9. doi: 10.3892/mmr.2013.1632. Epub 2013 Aug 14.
• Lizzi AR, Carnicelli V, Clarkson MM, Di Giulio A, Oratore A. Lactoferrin derived peptides: mechanisms of action and their perspectives as antimicrobial and antitumoral agents. Mini Rev Med Chem. 2009 Jun;9(6):687-95. doi: 10.2174/138955709788452757.
• Manzoni P, Rinaldi M, Cattani S, Pugni L, Romeo MG, Messner H, Stolfi I, Decembrino L, Laforgia N, Vagnarelli F, Memo L, Bordignon L, Saia OS, Maule M, Gallo E, Mostert M, Magnani C, Quercia M, Bollani L, Pedicino R, Renzullo L, Betta P, Mosca F, Ferrari F, Magaldi R, Stronati M, Farina D; Italian Task Force for the Study and Prevention of Neonatal Fungal Infections, Italian Society of Neonatology. Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. JAMA. 2009 Oct 7;302(13):1421-8. doi: 10.1001/jama.2009.1403.
• Manzoni P, Stolfi I, Messner H, Cattani S, Laforgia N, Romeo MG, Bollani L, Rinaldi M, Gallo E, Quercia M, Maule M, Mostert M, Decembrino L, Magaldi R, Mosca F, Vagnarelli F, Memo L, Betta PM, Stronati M, Farina D; Italian Task Force for the Study and Prevention of Neonatal Fungal Infections-the Italian Society of Neonatology. Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants: a randomized controlled trial. Pediatrics. 2012 Jan;129(1):116-23. doi: 10.1542/peds.2011-0279. Epub 2011 Dec 19.
• Mayeur S, Spahis S, Pouliot Y, Levy E. Lactoferrin, a Pleiotropic Protein in Health and Disease. Antioxid Redox Signal. 2016 May 10;24(14):813-36. doi: 10.1089/ars.2015.6458. Epub 2016 Mar 16.
• Meyer MP, Alexander T. Reduction in necrotizing enterocolitis and improved outcomes in preterm infants following routine supplementation with Lactobacillus GG in combination with bovine lactoferrin. J Neonatal Perinatal Med. 2017;10(3):249-255. doi: 10.3233/NPM-16130.
• Miotto M, Di Rienzo L, Bo L, Boffi A, Ruocco G, Milanetti E. Molecular Mechanisms Behind Anti SARS-CoV-2 Action of Lactoferrin. Front Mol Biosci. 2021 Feb 15;8:607443. doi: 10.3389/fmolb.2021.607443. eCollection 2021.
• Moreno-Navarrete JM, Ortega F, Sabater M, Ricart W, Fernandez-Real JM. Proadipogenic effects of lactoferrin in human subcutaneous and visceral preadipocytes. J Nutr Biochem. 2011 Dec;22(12):1143-9. doi: 10.1016/j.jnutbio.2010.09.015. Epub 2011 Feb 4.
• Moreno-Navarrete JM, Ortega FJ, Bassols J, Ricart W, Fernandez-Real JM. Decreased circulating lactoferrin in insulin resistance and altered glucose tolerance as a possible marker of neutrophil dysfunction in type 2 diabetes. J Clin Endocrinol Metab. 2009 Oct;94(10):4036-44. doi: 10.1210/jc.2009-0215. Epub 2009 Jul 7.
• Moreno-Navarrete JM, Ortega FJ, Ricart W, Fernandez-Real JM. Lactoferrin increases (172Thr)AMPK phosphorylation and insulin-induced (p473Ser)AKT while impairing adipocyte differentiation. Int J Obes (Lond). 2009 Sep;33(9):991-1000. doi: 10.1038/ijo.2009.143. Epub 2009 Aug 4.
• Nappi C, Tommaselli GA, Morra I, Massaro M, Formisano C, Di Carlo C. Efficacy and tolerability of oral bovine lactoferrin compared to ferrous sulfate in pregnant women with iron deficiency anemia: a prospective controlled randomized study. Acta Obstet Gynecol Scand. 2009;88(9):1031-5. doi: 10.1080/00016340903117994.
• Parekattil S.J., Esteves S.C., Agarwal A. Male Infertility. Springer; Berlin/Heidelberg, Germany: 2020. Harmful Effects of Antioxidant Therapy
• Poljsak B, Suput D, Milisav I. Achieving the balance between ROS and antioxidants: when to use the synthetic antioxidants. Oxid Med Cell Longev. 2013;2013:956792. doi: 10.1155/2013/956792. Epub 2013 Apr 29.
• Salaris C, Scarpa M, Elli M, Bertolini A, Guglielmetti S, Pregliasco F, Blandizzi C, Brun P, Castagliuolo I. Protective Effects of Lactoferrin against SARS-CoV-2 Infection In Vitro. Nutrients. 2021 Jan 23;13(2):328. doi: 10.3390/nu13020328.
• Sherman MP, Sherman J, Arcinue R, Niklas V. Randomized Control Trial of Human Recombinant Lactoferrin: A Substudy Reveals Effects on the Fecal Microbiome of Very Low Birth Weight Infants. J Pediatr. 2016 Jun;173 Suppl:S37-42. doi: 10.1016/j.jpeds.2016.02.074.
• Shi P, Fan F, Chen H, Xu Z, Cheng S, Lu W, Du M. A bovine lactoferrin-derived peptide induced osteogenesis via regulation of osteoblast proliferation and differentiation. J Dairy Sci. 2020 May;103(5):3950-3960. doi: 10.3168/jds.2019-17425. Epub 2020 Mar 18.
• Siqueiros-Cendon T, Arevalo-Gallegos S, Iglesias-Figueroa BF, Garcia-Montoya IA, Salazar-Martinez J, Rascon-Cruz Q. Immunomodulatory effects of lactoferrin. Acta Pharmacol Sin. 2014 May;35(5):557-66. doi: 10.1038/aps.2013.200.
• Tolone S, Pellino V, Vitaliti G, Lanzafame A, Tolone C. Evaluation of Helicobacter Pylori eradication in pediatric patients by triple therapy plus lactoferrin and probiotics compared to triple therapy alone. Ital J Pediatr. 2012 Oct 31;38:63. doi: 10.1186/1824-7288-38-63.
• Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med. 1998 Nov;26(11):1793-800. doi: 10.1097/00003246-199811000-00016.
• Wakabayashi H, Uchida K, Yamauchi K, Teraguchi S, Hayasawa H, Yamaguchi H. Lactoferrin given in food facilitates dermatophytosis cure in guinea pig models. J Antimicrob Chemother. 2000 Oct;46(4):595-602. doi: 10.1093/jac/46.4.595.
• Wakabayashi H, Yamauchi K, Abe F. Quality control of commercial bovine lactoferrin. Biometals. 2018 Jun;31(3):313-319. doi: 10.1007/s10534-018-0098-2. Epub 2018 Apr 4.
• Wang Y, Wang P, Wang H, Luo Y, Wan L, Jiang M, Chu Y. Lactoferrin for the treatment of COVID-19 (Review). Exp Ther Med. 2020 Dec;20(6):272. doi: 10.3892/etm.2020.9402. Epub 2020 Oct 27.
• Wu J, Chen J, Wu W, Shi J, Zhong Y, van Tol EA, Tang Q, Cai W. Enteral supplementation of bovine lactoferrin improves gut barrier function in rats after massive bowel resection. Br J Nutr. 2014 Aug 28;112(4):486-92. doi: 10.1017/S000711451400107X. Epub 2014 May 15.
• Yamauchi K, Wakabayashi H, Shin K, Takase M. Bovine lactoferrin: benefits and mechanism of action against infections. Biochem Cell Biol. 2006 Jun;84(3):291-6. doi: 10.1139/o06-054.

• Responsible Party: Ahmed H Hassan, PharmD, Principal Investigator, Mansoura University Hospital
• ClinicalTrials.gov Identifier: NCT05936528
• Other Study ID Numbers: MD.23.09.800; 35039/9/23
• First Posted: Jul 7, 2023
• Last Update Posted: Jul 7, 2023
• Last Verified: Jul 1, 2023

• Individual Participant Data (IPD) Sharing Statement: Yes
• Plan to Share IPD: Yes
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No
• Keywords provided by Ahmed H Hassan, PharmD, Principal Investigator, Mansoura University Hospital: Clinical outcomes; ICU patients; Lactoferrin
• Additional relevant MeSH terms: Critical Illness; Lactoferrin

Study Results

No Results Posted as of Jul 7, 2023